Clinical Trial: Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545083) titled 'Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)' on April 15.

Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell carcinoma.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

Intervention: DRUG: MRG003+Pucotenlimab

The participants will receive Pucotenlimab 200 mg (each 3-week/cycle) and ...